4-Acetylantroquinonol B enhances cell death and inhibits autophagy by downregulating the PI3K/Akt/MDR1 pathway in gemcitabine-resistant pancreatic cancer cells

Abstract

Gemcitabine (GEM) is a typical chemotherapeutic drug used to treat pancreatic cancer, but GEM resistance develops within weeks after chemotherapy. Hence, the development of a new strategy to overcome drug resistance is urgent. 4-Acetylantroquinonol B (4-AAQB), a ubiquinone derived from Taiwanofungus camphoratus, has hepatoprotective, anti-obesity, and antitumor activities. However, the role of 4-AAQB in enhancing GEM sensitivity is unclear. This study aimed to determine the underlying mechanisms by which 4-AAQB enhances cytotoxicity and GEM sensitivity. Cell viability was dramatically reduced by 4-AAQB (2 and 5 µM) treatment in the MiaPaCa-2 and GEM-resistant MiaPaCa-2 (MiaPaCa-2^GEMR) human pancreatic cancer cells. 4-AAQB led to cell cycle arrest, upregulated the levels of reactive oxygen species (ROS), promoted apoptosis, and inhibited autophagy, which subsequently enhanced GEM chemosensitivity by suppressing the receptor for advanced glycation end products (RAGE)/high mobility group box 1 (HMGB1)-initiated PI3K/Akt/multidrug resistance protein 1 (MDR1) signaling pathway in both cell lines. Vascular endothelial growth factor A (VEGFA) expression, cell migration, and invasion were also inhibited by the 4-AAQB incubation. Overall, this combination treatment strategy might represent a novel approach for GEM-resistant pancreatic cancer.

Introduction

According to cancer statistics from the American Cancer Society, pancreatic cancer is characterized by the lowest 5-year survival rate (10%) among all cancers (1). In addition, early diagnosis is extremely difficult due to the nonspecific symptoms of pancreatic cancer (2). Notably, 80–85% of patients with local invasion and distant metastasis at the diagnosis of pancreatic cancer receive systemic therapy with gemcitabine (3). Gemcitabine (GEM), a deoxycytidine nucleotide analog, is a typical first-line chemotherapeutic drug for pancreatic cancer treatment. Unfortunately, GEM resistance frequently occurs in patients with pancreatic cancer, which results in a high incidence, high mortality, and substantial disease burden in patients (4,5). In addition, a 5-year survival rate below 5% is found in patients with drug-resistant and metastatic pancreatic cancer, suggesting that drug resistance is a critical problem that urgently needs to be solved (6). The available evidence described above indicates that a late diagnosis and high therapeutic resistance are the major challenges in pancreatic cancer treatment. Thus, the development of a new strategy designed to enhance GEM chemosensitivity may be beneficial for pancreatic cancer treatment.

Taiwanofungus camphoratus (Antrodia cinnamomea), often referred to as ‘Niu-chang-chih’, is a medicinal fungus that only grows on the native tree Cinnamomum kanehirai Hayata in Taiwan (7). Several bioactive compounds are present in Taiwanofungus camphoratus, including polysaccharides, triterpenes, diterpenes, succinic acid derivatives, and ubiquinone (7). 4-Acetylantroquinonol B (4-AAQB) is the ubiquinone derivative of Taiwanofungus camphoratus, which is identified as the major antiproliferative compound for hepatoma cells (8). In addition, 4-AAQB is known to participate in modulating many physiological and pathological processes, such as anti-inflammatory and antioxidant ability (9), amelioration of nonalcoholic steatohepatitis (9) and inhibition of osteoclast formation (10), breast cancer (11), glioblastoma (12), and hepatic cancer stem cell tumorigenicity (13).

High mobility group box 1 (HMGB1) and the receptor for advanced glycation end products (RAGE) are crucial for tumor progression, drug resistance, and metastasis in pancreatic adenocarcinoma (14,15). Accumulating evidence suggests that RAGE expression is elevated in pancreatic cancer and pancreatic cancer cell lines but not in adjacent normal epithelial tissue (16,17). Moreover, our previous study found that RAGE/HMGB1 upregulates the expression of MDR1 in GEM-resistant MiaPaCa-2 (MiaPaCa-2^GEMR) cells (18–20). This indicates that RAGE/HMGB1 plays a crucial role in pancreatic cancer progression and chemoresistance. However, the roles of 4-AAQB in suppressing pancreatic cancer and enhancing GEM chemosensitivity remain unclear. The aim of this study was to investigate the underlying mechanisms of cytotoxicity and enhanced chemosensitivity mediated by 4-AAQB treatment in human pancreatic cancer MiaPaCa-2 and MiaPaCa-2^GEMR cells.

Materials and methods

Chemicals

4-Acetylantroquinonol B (4-AAQB) was kindly provided by Grape King Bio Ltd. Sodium bicarbonate (NaHCO₃), 2′,7′-dichlorofluorescein diacetate (DCFH-DA), penicillin-streptomycin solution (PS), MTT, DMSO, TEMED, SDS, glycine, Tris, isopropanol, Tween-20, bovine serum albumin (BSA), Triton X-100, sodium chloride (NaCl), and GEM were purchased from MilliporeSigma. Propidium iodide (PI) and Annexin V staining kit (cat. no. 559763) was purchased from BD Biosciences. BCA protein assay kit (BC03-500) was purchased from Energenesis Biomedical. β-actin (cat. no. NB600-501), Beclin-1 (cat. no. NB110-87318), vascular endothelial growth factor-A (cat. no. VEGFA, NB100-664), LC3 II (cat. no. NB100-2220), and Atg5 (cat. no. NB110-53818) antibodies were purchased from Novus Biologicals. Bax (cat. no. 5023), Bcl-xL (cat. no. 2762), PI3K (cat. no. 4292), phospho-PI3K (cat. no. 4228), Akt (cat. no. 9272), phospho-Akt (cat. no. 9271), HMGB1, PI3K catalytic subunit type III (Vps34; cat. no. 4263), and MDR1 (cat. no. 6893) antibodies were obtained from Cell Signaling Technology, Inc. The anti-RAGE (cat. no. PA5-24787) antibody was purchased from Invitrogen (Thermo Fisher Scientific, Inc.). Dulbecco's modified eagle medium (DMEM) high glucose medium, fetal bovine serum (FBS), and horse serum were purchased from Gibco (Thermo Fisher Scientific, Inc.).

Cell culture

The Homo sapiens pancreatic cancer cell line MiaPaCa-2 was purchased from the Bioresource Collection and Research Center (Hsinchu, Taiwan). The GEM-resistant MiaPaCa-2^GEMR cell line was established by gradually increasing GEM concentrations to 0.5 µM GEM to induce tolerance as described in a previous report (21). Cells were cultured in DMEM (high glucose) medium supplemented with 10% fetal bovine serum (FBS) plus 2.5% horse serum and 1% PS antibiotic solution (100 U/ml penicillin and 100 µg/ml streptomycin). The two cell lines were maintained in a 37°C incubator with 5% CO₂.

Cell viability

MiaPaCa-2 and MiaPaCa-2^GEMR cells (8×10³ cells/well) were cultured in a 96-well plate overnight. The cells were incubated with various concentrations (0.1–5 µM) of 4-AAQB at 37°C for 48 h. The medium was discarded, and the cells were washed in PBS three times. Cells were incubated with MTT solution (0.5 mg/ml) for 1 h at 37°C. The MTT solution was removed and the formazan crystals were dissolved in 200 µl DMSO. Cell viability was determined using a microplate reader (FLUOstar Omega) at 570 nm and calculated as: Cell viability (%) = Absorbance of the sample/Absorbance of the control) ×100.

Reactive oxygen species (ROS) measurement

MiaPaCa-2 and MiaPaCa-2^GEMR cells (6×10⁴ cells/well) were cultured in a 24-well plate overnight. Cells were treated with 4-AAQB (2 and 5 µM) with or without GEM at 37°C for 48 h. The cells were then incubated with DCFH-DA at 37°C for 30 min. The cellular ROS level was measured using a Fluostar Galaxy reader (BMG Labtechnologies Ltd.) with maximum excitation and emission spectra of 485 and 520 nm, respectively. The level of ROS was calculated as the rate of change in contrast to the level in untreated cells.

Cell cycle analysis

MiaPaCa-2 and MiaPaCa-2^GEMR cells (6×10⁴ cells/ml) were cultured in a 6-well plate overnight. Cells were incubated with various concentrations (2 and 5 µM) of 4-AAQB at 37°C for 48 h. The medium was discarded and cells were washed with PBS three times. Cells were harvested by trypsinization and fixed with 70% ethanol at −20°C for 2 h. Cells (1×10⁵) were stained with 0.5 ml PI/RNase staining buffer (cat. no. 550825, BD Biosciences) at room temperature for 30 min. The cell cycle was evaluated using a BD Accuri C6 Plus flow cytometer (BD Biosciences). The cell cycle phase distribution was analyzed by ModFit LT 3.1 software (Verity Software House).

Annexin V and PI staining

MiaPaCa-2 and MiaPaCa-2^GEMR cells (6×10⁴ cells/ml) were cultured in a 6-well plate overnight. Cells were incubated with 4-AAQB (2 and 5 µM) at 37°C for 48 h, double-stained with Annexin V and PI at room temperature for 15 min and analyzed using a BD Accuri C6 Plus flow cytometer (BD Biosciences). Quadrant 1 (negative for Annexin V and PI) indicates living cells, quadrant 2 (Annexin V-positive, PI-negative) indicates early apoptotic cells, quadrant 3 (positive for Annexin V and PI) indicates the late apoptotic cells, and quadrant 4 (Annexin V-negative, PI-positive) indicates necrotic cells. The data was analyzed by ModFit LT 3.1 software (Verity Software House).

Western blot analysis

MiaPaCa-2 and MiaPaCa-2^GEMR cells (1×10⁶) were incubated with 4-AAQB (2 and 5 µM) at 37°C for 48 h. The expression of proteins related to apoptosis (Bcl-xL and Bax), autophagy (Atg5, Beclin-1, and LC3 II), and GEM resistance-associated signaling (PI3K, phospho-PI3K, Akt, phospho-Akt, Vps34, RAGE, HMGB1, and MDR1) was determined using western blotting as described in a previous report (21). Briefly, cells were lysed by ice-cold RIPA lysis buffer (Thermo Fisher Scientific, Inc.) containing a cocktail of 1% protease inhibitors (P&C Biotech, Inc.) and 1% phosphatase inhibitors (P&C Biotech, Inc.), and the protein concentration was determined using a BCA protein assay kit (Energenesis Biomedical Co., Ltd.) according to the user guide. A total of 50 µg protein per lane was separated using 10–12% SDS-PAGE, then transferred to PVDF membranes and blocked with 5% non-fat milk in TBS-0.1% Tween-20 (TBST) at room temperature for 1 h. PVDF membranes were incubated primary antibodies (1:1,000) overnight at 4°C. After washing three times with TBST at room temperature for 10 min, the membranes were incubated HRP-conjugated secondary antibodies (1:10,000) at room temperature for 2 h. After antibody incubation, the protein was visualized using the ECL detecting reagent (PerkinElmer, Inc.), and the density of the target protein bands was quantified with the corresponding internal reference proteins by the Biospectrum 810 UVP VisionWorks LS Image Acquisition and Analysis Software (UVP).

Chemosensitivity analysis

MiaPaCa-2 and MiaPaCa-2^GEMR cells (4×10⁴ cells/ml) were cultured in a 96-well plate overnight. The increase in chemosensitivity was evaluated through both cotreatment with 4-AAQB and GEM and 4-AAQB pretreatment methods. For cotreatment, cells were incubated with 4-AAQB (2 and 5 µM) plus GEM at 37°C for 48 h. For pretreatment, cells were pretreated with 4-AAQB (2 and 5 µM) at 37°C for 48 h and then incubated with GEM at 37°C for another 48 h. In the pretreatment method, cells unexposed to 4-AAQB or GEM were incubated in complete medium until the end of the experiment. After treatments, chemosensitivity was determined using the MTT analysis.

Cell migration assay

Cell migration was evaluated using a gap closure assay. The Ibidi^® culture inserts were placed in a 24-well plate, and then MiaPaCa-2 and MiaPaCa-2^GEMR cells (5×10⁵ cells/ml) were seeded into the inserts and cultured with complete medium overnight. After cell attachment, the culture insert was removed and then the migration distance was recorded after exposure to 4-AAQB (2 and 5 µM) with or without GEM (0.5 µM) at 37°C for 48 h in serum free condition. The cell migration rate was calculated using ImageJ software (version 1.34s; National Institutes of Health). The migration area of the various treatment groups was calculated as a percentage of the untreated group using the following formula: Mean migration area of the experimental group/mean migration area of the control group ×100%.

Cell invasion assay

Cell invasion was measured using a Transwell^® system with an 8-µm pore size (Corning, Inc.) as described previously (22). Briefly, 0.5 mg/ml Matrigel (Thermo Fisher Scientific, Inc.) was coated on the upper chambers of the inserts at 37°C for 1 h. MiaPaCa-2 and MiaPaCa-2^GEMR cells (5×10⁴ cells/well) were cultured with 4-AAQB (2 and 5 µM) under serum-free conditions at 37°C for 48 h on the upper chambers and medium containing 10% FBS served as a chemoattractant in the lower chambers. The invading cells were subsequently fixed in 100% methanol for 10 min at room temperature, stained with 0.5% crystal violet for 10 min at room temperature. The total invasive number of cells was calculated using the Power IX71 Inverted Fluorescence Microscope (Olympus Corporation).

Statistical analysis

All experiments were repeated independently three times. The data were analyzed using one-way ANOVA followed by Tukey's post hoc test using the SPSS 20 software (IBM, Corp.) and are shown as the mean ± SD. P<0.05 was considered to indicate a statistically significant difference.

Results

4-AAQB induces cytotoxicity and cell cycle arrest in pancreatic cancer cells

MiaPaCa-2^GEMR cells were generated to explore the molecular mechanisms of GEM resistance in pancreatic cancer cells (21). The structure of 4-AAQB is shown in Fig. 1A. The effect of 4-AAQB on cell viability was evaluated in both MiaPaCa-2 and MiaPaCa-2^GEMR cells. Cytotoxicity was significantly increased by 4-AAQB treatment in a dose-dependent manner (0.1–5 µM) for 48 h (Fig. 1B and C). The IC₅₀ values of 4-AAQB in MiaPaCa-2 and MiaPaCa-2^GEMR cells were 1.61 and 3.8 µM, respectively (Fig. 1B and C). Doses of 2 and 5 µM were used in subsequent experiments.

Figure 1.

4-AAQB treatment inhibits cell cycle progression and viability. (A) Structure of 4-AAQB. (B) MiaPaCa-2 and (C) MiaPaCa-2^GEMR cell viability was determined using MTT assays. Cell cycle analysis of (D) MiaPaCa-2 and (E) MiaPaCa-2^GEMR cells was carried out using flow cytometry. *P<0.05, **P<0.01, and ***P<0.001 vs. the untreated control cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant.

Cell viability is directly affected by cell cycle arrest, apoptosis, and autophagy in cancer cells (18). S-phase cell cycle arrest was observed in MiaPaCa-2 cells subjected to 4-AAQB treatment, whereas the percentage of G0/G1 phase cells was significantly reduced in 4-AAQB-treated MiaPaCa-2 cells compared with untreated MiaPaCa-2 cells (Fig. 1D). In addition, this coordinated change in G2/M cell cycle arrest was observed in 4-AAQB-treated MIAPaCa-2^GEMR cells (Fig. 1E). Previous studies have found that cell cycle regulators not only influence cell division but also induce programmed cell death (23). In the present study, treatment with 4-AAQB led to dose-dependent cell cycle arrest, suggesting that 4-AAQB treatment may inhibit cell cycle progression in pancreatic cancer cells.

4-AAQB treatment promotes apoptosis and inhibits autophagy

Emerging evidence suggests that to increase apoptosis and decrease autophagy are powerful therapeutic strategies for pancreatic cancer progression (24). In the present study, the percentage of late apoptotic cells was significantly induced in a dose-dependent manner following 4-AAQB treatment in both cell lines (Fig. 2). Western blot analysis was used to examine the expression of apoptosis-associated proteins. Consistent with published evidence (24), although the levels of Bcl-xL were not significantly altered by 2 µM 4-AAQB treatment, however, it was significantly reduced following 5 µM 4-AAQB treatment in MiaPaCa-2^GEMR cells compared with the untreated cells (Fig. 3A and B). The levels of Bax significantly increased in MiaPaCa-2^GEMR cells treated with 4-AAQB (Fig. 3A and C). Moreover, the Bax/Bcl-xL ratio significantly increased in 5 µM 4-AAQB-treated MiaPaCa-2 and MiaPaCa-2^GEMR cells (Fig. 3D).

Figure 2.

4-AAQB promotes apoptosis in MiaPaCa-2 and MiaPaCa-2^GEMR cells. The cells were treated with the indicated concentrations of 4-AAQB for 48 h. Annexin V/propidium iodide staining was carried out to detect apoptotic cells using flow cytometry. *P<0.05 vs. the untreated control cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant; FITC, fluorescein isothiocyanate; EA, early apoptosis; LA, late apoptosis.

Figure 3.

4-AAQB upregulates the expression of apoptosis-associated proteins in MiaPaCa-2 and MiaPaCa-2^GEMR cells. The cells were treated with the indicated concentrations of 4-AAQB for 48 h. (A) The expression levels of apoptosis-associated proteins (Bcl-xL and Bax) were assessed using western blotting. (B and C) Semi-quantification of Bcl-xL and Bax protein expression. (D) Bax/Bcl-xL ratio. *P<0.05 vs. the untreated control cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant.

The pro-apoptotic protein Bax directly inhibits autophagy (25). Furthermore, clinical evidence has revealed that autophagy is involved in resistance to gemcitabine/nab-paclitaxel chemotherapy and its cytotoxic response in patients with pancreatic cancer (26). Thus, the expression levels of autophagy-associated proteins (Atg5, Beclin-1 and LC3 II) were assessed using western blotting. The protein expression levels of Atg5 and LC3 II were significantly reduced after 4-AAQB treatment in both cell lines compared with the untreated cells (Fig. 4).

Figure 4.

4-AAQB treatment downregulates the levels of autophagy-associated proteins in MiaPaCa-2 and MiaPaCa-2^GEMR cells. (A) The expression of Atg5, Beclin-1 and LC3 II was analyzed using western blotting. (B-D) Semi-quantification of Atg5, Beclin-1 and LC3 II protein levels. *P<0.05 vs. the untreated control cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant; Atg5, autophagy-related 5.

The PI3K/Akt signaling pathway is critical for tumor survival and autophagy initiation (27,28). The phosphorylation of PI3K and Akt significantly decreased in 4-AAQB-treated MiaPaCa-2 and MiaPaCa-2^GEMR cells compared with untreated cells (Fig. 5A-C). Vps34 binds to beclin-1 and subsequently activates autophagy (29). Additionally, a previous study indicated that VPS34 was essential for the autophagy process (30). In the present study, the expression of the Vps34 protein was significantly reduced following the 4-AAQB incubation in both cell lines (Fig. 5D and E).

Figure 5.

4-AAQB downregulates the expression of the PI3K, Akt and Vps34 proteins in MiaPaCa-2 and MiaPaCa-2^GEMR cells. (A) The levels of P-PI3K, PI3K, p-Akt and Akt were analyzed using western blotting. (B) Semi-quantification of p-PI3K/PI3K protein levels. (C) Semi-quantification of p-Akt/Akt protein levels. (D) The expression of Vps34 was analyzed using western blotting. (E) Semi-quantification of Vps34 protein levels. *P<0.05 and **P<0.01 vs. the untreated control cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant; p-, phosphorylated; Vps34, phosphatidylinositol 3-kinase catalytic subunit type 3.

Chemosensitivity and ROS levels are enhanced through the suppression of the RAGE-HMGB1-initiated PI3K/Akt/MDR1 signaling axis in both cell lines treated with 4-AAQB

As shown in our previous study, the PI3K/Akt/MDR1 axis is triggered by HMGB1 and RAGE engagement during GEM chemoresistance (19). Thus, the protein expression levels of HMGB1, RAGE, and MDR1 were examined. The levels of HMGB1 and RAGE were significantly inhibited after 5 µM 4-AAQB treatment in MiaPaCa-2 cells (Fig. 6A-C). Moreover, treatment with both 2 and 5 µM 4-AAQB effectively inhibited HMGB1 and RAGE expression in MiaPaCa-2^GEMR cells (Fig. 6A-C). Accordingly, the level of the MDR1 protein was reduced by 4-AAQB treatment in a dose-dependent manner in both cell lines (Fig. 6D and E).

Figure 6.

4-AAQB treatment downregulates HMGB1, RAGE and MDR1 protein expression. (A) The expression of HMGB1 and RAGE was analyzed using western blotting. (B and C) Semi-quantification of HMGB1 and RAGE protein levels. (D) The expression of MDR1 was analyzed using western blotting. (E) Semi-quantification of MDR1 protein levels. *P<0.05 vs. the untreated control cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant; HMGB1, high mobility group box 1 protein; MDR1, multidrug resistance protein 1; RAGE, receptor for advanced glycation end-products.

A previous study showed that suppression of the PI3K/AKT pathway by inducing ROS generation may represent a strategy for cancer treatment (31). Additionally, GEM induces ROS, resulting in an increase in pancreatic cancer cell death, although the opposite effect is observed in GEM-resistant cells (32). In the present study, ROS levels were measured using DCFH-DA staining. The results showed that ROS levels significantly increased in a dose-dependent manner following 4-AAQB treatment in both cell lines (Fig. 7A and B). Notably, ROS accumulation was dramatically increased by 4-AAQB combination with GEM treatment in MiaPaCa-2^GEMR cells compared with 4-AAQB-treated alone or GEM-treated alone condition (Fig. 7B).

Figure 7.

4-AAQB treatment leads to cellular ROS accumulation. MiaPaCa-2 and MiaPaCa-2^GEMR cells were treated with the indicated concentrations of 4-AAQB and GEM for 48 h. The ROS levels of (A) MiaPaCa-2 and (B) MiaPaCa-2^GEMR cells were measured using a DCFH-DA probe. *P<0.05 and **P<0.01 vs. the untreated control cells; ^##P<0.01 and ^###P<0.001 vs. the gemcitabine treated cells; ^@P<0.05 vs. the 4-AAQB treated cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant; ROS, reactive oxygen species.

Pancreatic cancer is highly malignant with great metastatic capacity (33). An increase in chemosensitivity is important for preventing the local invasion and long distant metastasis of pancreatic cancer (34). The ability of 4-AAQB to increase chemosensitivity was evaluated using 4-AAQB cotreatment with GEM and 4-AAQB pretreatment methods in both cell lines to select an effective drug treatment pattern. Consistent with the results presented in Fig. 1B, cell viability was significantly reduced by GEM and 4-AAQB (2 and 5 µM) treatment in MiaPaCa-2 cells compared with untreated cells (Fig. 8A). Compared with GEM treatment, chemosensitivity was effectively enhanced following 4-AAQB cotreatment with GEM in MiaPaCa-2 cells (Fig. 8A). Cell viability was not altered following 0.5 µM GEM treatment in MiaPaCa-2^GEMR cells (Fig. 8B), indicating that the GEM-resistant pancreatic cancer cell lines was successfully established. Cell viability was significantly reduced both by 4-AAQB treatment alone and by 4-AAQB/GEM co-treatment in cells (Fig. 8B). In addition, the effect of the 4-AAQB pre-treatment on enhancing chemosensitivity was also evaluated. Cells were pretreated with 4-AAQB for 48 h, then incubated with GEM for another 48 h. In MiaPaCa-2 cells, the GEM and 4-AAQB (2 and 5 µM) treatment significantly reduced cell viability (Fig. 8C). Additionally, chemosensitivity was significantly increased following 4-AAQB pre-treatment in MiaPaCa-2 cells compared with GEM-treated cells (Fig. 8C). In addition, cell viability was significantly inhibited following 4-AAQB (2 and 5 µM) pre-treatment with or without GEM incubation in MiaPaCa-2^GEMR cells (Fig. 8D).

Figure 8.

4-AAQB enhances chemosensitivity to gemcitabine. (A and B) MiaPaCa-2 and MiaPaCa-2^GEMR cells were treated with the indicated concentrations of 4-AAQB and GEM for 48 h. The viability of (A) MiaPaCa-2 and (B) MiaPaCa-2^GEMR cells was determined using MTT assays. (C and D) The cells were pretreated with 4-AAQB (2 and 5 µM) for 48 h and then incubated with GEM for another 48 h. The viability of (C) MiaPaCa-2 and (D) MiaPaCa-2^GEMR cells was determined using MTT assays. *P<0.05 **P<0.01, and ***P<0.001 vs. the untreated control cells; ^#P<0.05 and ^##P<0.01 vs. the gemcitabine treated cells; ^@P<0.05 vs. the 4-AAQB treated cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant.

4-AAQB treatment effectively repressed VEGFA-mediated cell migration and invasion. VEGFA plays important roles in cell proliferation, angiogenesis, migration, invasion, and cancer metastasis (35). According to a previous study, the upregulation of VEGFA in patients with pancreatic cancer is associated with metastatic disease and shorter overall survival (36). The next experiments were carried out to assess whether 4-AAQB treatment was effective at inhibiting VEGFA production and subsequently preventing cell migration and invasion. Interestingly, VEGFA protein levels significantly decreased in both cell lines subjected to 4-AAQB treatment (Fig. 9A and B). Cell migration was inhibited following 4-AAQB, GEM, and 4-AAQB/GEM co-treatment in MiaPaCa-2 cells compared with untreated cells (Fig. 9C and D). Unexpectedly, the cell migration distance was not substantially reduced by 4-AAQB/GEM co-treatment compared to 4-AAQB treatment alone in MiaPaCa-2 cells (Fig. 9C and D). In addition, 4-AAQB (2 and 5 µM) treatment effectively decreased MiaPaCa-2^GEMR cell migration compared to untreated cells (Fig. 9E and F). Notably, 2 µM 4-AAQB/GEM co-treatment significantly decreased cell migration compared to that of 4-AAQB-treated MiaPaCa-2^GEMR cells (Fig. 9E and F). In addition, the inhibitory effect of 4-AAQB on cell invasion was also evaluated. The cell invasion abilities of MiaPaCa-2 and MiaPaCa-2^GEMR cells were significantly reduced by 4-AAQB (2 and 5 µM) treatment (Fig. 10). Notably, 4-AAQB combined with GEM significantly enhanced the inhibition of cell invasion compared with 4-AAQB-treated MiaPaCa-2 cells l and MiaPaCa-2^GEMR cells (Fig. 10B and D).

Figure 9.

4-AAQB downregulates VEGFA expression and inhibits cell migration. (A) The expression of the VEGFA protein was analyzed using western blotting. (B) Semi-quantification of VEGFA protein levels. (C and E) Cell migration was assessed using a wound-healing assay. Multiple images were captured of each well at various time points. Magnification, ×100. (D and F) The migration distances were recorded and calculated using ImageJ software. *P<0.05 **P<0.01, and ***P<0.001 vs. the untreated control cells; ^#P<0.05 and ^##P<0.01 vs. the gemcitabine treated cells; ^@P<0.05 vs. the 4-AAQB treated cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant.

Figure 10.

4-AAQB inhibits the invasiveness of MiaPaCa-2 and MiaPaCa-2^GEMR cells. Cells were treated with 4-AAQB (2 and 5 µM) for 48 h. (A) MiaPaCa-2 cell invasion was assessed using a Transwell assay. Representative images of the invasive cells are shown. (B) The number of invasive MiaPaCa-2 cells was calculated. (C) MiaPaCa-2^GEMR cell invasion was assessed using a Transwell assay. Representative images of the invasive cells are shown. (D) The number of invasive MiaPaCa-2^GEMR cells was calculated. *P<0.05 and **P<0.01 vs. the untreated control cells; ^#P<0.05, ^##P<0.01, and ^###P<0.001 vs. the gemcitabine treated cells; ^@P<0.05 and ^@@P<0.01 vs. the 4-AAQB treated cells. 4-AAQB, 4-Acetylantroquinonol B; GEMR, gemcitabine-resistant.

Discussion

GEM is known to induce ROS accumulation, cell cycle arrest, and apoptosis (37,38). However, GEM resistance inhibits ROS production and consequently inhibits cell death in pancreatic ductal adenocarcinoma (32). 4-AAQB triggers cell cycle arrest, apoptosis, and DNA damage by suppressing CDK2/CDK4 expression in human breast cancer and hepatocellular carcinoma cells (11,39). The present study also found that 4-AAQB upregulated cell cycle arrest and apoptosis. This suggested that 4-AAQB may play a vital role in regulating cyclin-dependent kinases (CDKs) in pancreatic cancer cells and the cell cycle-related markers such as CDK1, CDK2, CDK4 or CDK5 were not further evaluated; however, this should be further analyzed in future in vitro studies. Moreover, RAGE downregulation in pancreatic tumor cells is sensitive to H₂O₂-induced oxidative injury, indicating that RAGE plays a protective role against oxidative injury (40,41). In the present study, 4-AAQB treatment effectively induced ROS accumulation by inhibiting RAGE/HMG1 levels and promoting cell cycle arrest and apoptosis in both MiaPaCa-2 and GEM-resistant cells. The cumulative evidence suggests 4-AAQB plays an important role the regulation of cancer cell death.

4-AAQB is a novel bioactive compound, and its effect on GEM chemosensitivity remains unclear. A previous study has reported that 4-AAQB plays a critical role in inhibiting tumor growth by attenuating cisplatin chemoresistance and inhibiting Atg5-dependent autophagy in ovarian cancer (42). Increased autophagy in pancreatic cancer is strongly associated with early metastasis and chemotherapy resistance, indicating that autophagy may serve as a therapeutic target for pancreatic cancer (43). Additionally, a clinical trial found that the administration of an autophagy inhibitor (hydroxychloroquine) in combination with GEM therapy effectively increases the survival rate through the activation of immune responses in patients with resectable pancreatic cancer (26). The findings of the present study revealed that autophagy-associated protein (LC3 II and Atg5) levels and GEM resistance were significantly reduced in 4-AAQB-treated cells.

Based on accumulating evidence, apoptosis and autophagy may compete with each other; for example, tioconazole represses autophagy-related 4A cysteine peptidase (ATG4A) and ATG4B expression, which subsequently enhances chemotherapy-induced apoptosis in glioma, colorectal, and breast cancer cells (44). Additionally, spautin-1 (an autophagy inhibitor) has been shown to increase apoptosis by inactivating the PI3K/Akt pathway in chronic myeloid leukemia cells (45). Moreover, a previous report found that cell cycle arrest and apoptosis were induced in 4-AAQB-treated MDA-MB-231 and Hs578T human breast cancer cells (11). The findings from the present study corroborate the aforementioned results and indicate that 4-AAQB induces cell cycle arrest, apoptosis, and GEM chemosensitivity by inhibiting autophagy and the PI3K/Akt signaling axis.

Our previous studies demonstrated that the RAGE/HMGB1-initiated PI3K/Akt/MDR1 biochemical cascade was strongly related to GEM chemoresistance in human pancreatic cancer cells and xenograft mouse models (18–21). Moreover, 4-AAQB has been shown to suppress autophagy and enhance cisplatin sensitivity by suppressing PI3K/Akt/mTOR/p70S6K signaling in ovarian cancer cells (46). In addition, PI3K/Akt signaling is the dominant regulator of the epithelial-mesenchymal transition (EMT), which contributes to tumor migration, invasion, and metastasis (47). 4-AAQB (5–10 µM) treatment significantly downregulated VEGF and reduced cell migration and invasion in a dose-dependent manner in DLD-1, HT-29, and HCT-116 colorectal cancer cells (48,49). In addition, previous evidence showed that cell migration studies had shown the importance of cell moving ability; however, a 2D substrate (Matrigel matrix) was used in the evaluation of cell invasion that may deliver inconsistent results due to cell adhesion with a different substrate such as polystyrene cell culture plate or Matrigel matrix-coated (50). A previous study compared the motility-associated protein profiles between human bladder cancer T24T cells (higher invasion but lower migration abilities) and its parental non-metastatic T24 cells (51). The results has demonstrated that high cell migratory activity does not necessarily mean high invasive activity in highly metastatic human bladder cancer T24T cells via SOD2 and MMP-2 regulated metastatic behaviors (51). Although the inhibitory effect of 4-AAQB/GEM co-treatment on invasion was greater than that on migration of MiaPaCa-2 cells, cell migration and invasion were reduced by 4-AAQB treatment in both MiaPaCa-2 and GEM-resistant cells, suggesting that 4-AAQB may play a critical role in the inhibition of tumor metastasis.

In conclusion, the present study described the mechanism through which 4-AAQB downregulates autophagy and enhances cytotoxicity, ROS accumulation, cell cycle arrest, apoptosis, and GEM sensitivity through the suppression of the RAGE/HMGB1-initiated PI3K/Akt/MDR1 signaling pathway in pancreatic cancer cells. Accordingly, this 4-AAQB/GEM combination strategy might represent a novel approach for the treatment of GEM-resistant pancreatic cancer.

Glossary

Abbreviations

4-AAQB

4-acetylantroquinonol B

ATG5

autophagy-related protein 5

HMGB1

high mobility group box 1 protein

MDR1

multidrug resistance protein 1

RAGE

receptor for advanced glycation end-products

VEGFA

vascular endothelial growth factor A

Funding Statement

This research work was supported by a grant from Grape King Bio Ltd., Taiwan (grant no. BR-MM003).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YYC and GCY conceived and designed the experiments. YYC, TJL and SYC performed the experiments. YYC, TWL, SYC and CCC analyzed and interpreted the data. SYC, and GCY wrote the manuscript. YYC, SYC, and GCY confirmed the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors TJL, TWL, CCC are employed by Grape King Bio Ltd. All the authors declare that they have no competing interests.